文献速递系统性红斑狼疮

贝利尤单抗治疗系统性红斑狼疮患者的结局:五项III期临床试验基于英国群岛狼疮评估组组合狼疮评估标准的事后疗效分析

Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.
PubMed 文献 · RMD Open · 2025-04-23

该事后分析纳入五项贝利尤单抗治疗活动性成人系统性红斑狼疮的随机对照试验,共3086例患者接受贝利尤单抗(n=1869)或安慰剂(n=1217)。第52周时,贝利尤单抗在BLISS-52、BLISS-NEA和BLISS-SC试验中BICLA缓解频率均高于安慰剂,汇总人群亦显示高度显著差异。

要点

  • 第52周BICLA缓解频率贝利尤单抗高于安慰剂:BLISS-52 OR 1.49(95%CI 1.05-2.12;p=0.024),BLISS-NEA OR 1.62(95%CI 1.12-2.33;p=0.010),BLISS-SC OR 1.89(95%CI 1.39-2.57;p<0.001)。
  • 汇总人群BICLA缓解频率贝利尤单抗高于安慰剂:OR 1.47(95%CI 1.25-1.72;p<0.001;校正试验变异)。
  • 无论基线糖皮质激素剂量(>7.5或≤7.5 mg/天泼尼松等效)、基线SLEDAI-2K≥10、基线抗dsDNA阳性伴/或低C3/C4水平,贝利尤单抗BICLA缓解频率均高于安慰剂。

核心结论

  • 在五项评估贝利尤单抗治疗系统性红斑狼疮的随机对照试验分析中,贝利尤单抗在总体研究人群及基线高整体或血清学活动度亚组中BICLA缓解优于安慰剂。
  • 贝利尤单抗联合抗疟药时获益更突出。

研究设计与样本

  • 对五项活动性成人系统性红斑狼疮随机对照试验进行事后分析:四项静脉贝利尤单抗试验(BLISS-52、BLISS-76、BLISS-NEA、EMBRACE)和一项皮下贝利尤单抗试验(BLISS-SC)。
  • 分析各试验第52周里程碑评估,共3086例患者接受贝利尤单抗(n=1869)或安慰剂(n=1217)。
  • 治疗缓解按BICLA标准定义:BILAG改善;基于BILAG和系统性红斑狼疮疾病活动指数-2K的疾病活动度无恶化;医师总体评估无恶化≥0.3(量表0-3);无治疗失败。

主要发现

  • 第52周BICLA缓解频率贝利尤单抗高于安慰剂:BLISS-52 OR 1.49(95%CI 1.05-2.12;p=0.024),BLISS-NEA OR 1.62(95%CI 1.12-2.33;p=0.010),BLISS-SC OR 1.89(95%CI 1.39-2.57;p<0.001)。
  • 汇总人群BICLA缓解频率贝利尤单抗高于安慰剂:OR 1.47(95%CI 1.25-1.72;p<0.001;校正试验变异)。
  • 无论基线糖皮质激素剂量(>7.5或≤7.5 mg/天泼尼松等效)、基线SLEDAI-2K≥10、基线抗dsDNA阳性伴/或低C3/C4水平,贝利尤单抗BICLA缓解频率均高于安慰剂。
  • 贝利尤单抗联合抗疟药时BICLA缓解达成频率更高。

关键数值与推荐

  • BICLA缓解定义:BILAG改善;基于BILAG和系统性红斑狼疮疾病活动指数-2K的疾病活动度无恶化;医师总体评估无恶化≥0.3(量表0-3);无治疗失败。
  • 第52周BICLA缓解频率贝利尤单抗高于安慰剂:BLISS-52 OR 1.49(95%CI 1.05-2.12;p=0.024),BLISS-NEA OR 1.62(95%CI 1.12-2.33;p=0.010),BLISS-SC OR 1.89(95%CI 1.39-2.57;p<0.001)。
  • 汇总人群BICLA缓解频率贝利尤单抗高于安慰剂:OR 1.47(95%CI 1.25-1.72;p<0.001;校正试验变异)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine belimumab efficacy assessed using the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) in patients with systemic lupus erythematosus (SLE) from phase III belimumab randomised controlled trials (RCTs). METHODS: A post hoc analysis was carried out on five RCTs in active adult SLE: four with intravenous (BLISS-52, BLISS-76, BLISS-NEA, EMBRACE) and one with subcutaneous belimumab (BLISS-SC). The 52-week landmark assessments were analysed across trials. Treatment response was defined according to BICLA criteria (BILAG improvement; no worsening of disease activity based on BILAG and Systemic Lupus Erythematosus Disease Activity Index-2K; no deterioration in Physician's Global Assessment ≥0.3 (scale: 0-3); no treatment failure). RESULTS: A total of 3086 patients received belimumab (n=1869) or placebo (n=1217). BICLA response frequencies at week 52 were greater with belimumab vs placebo in BLISS-52 (OR (95% CI): 1.49 (1.05-2.12); p=0.024), BLISS-NEA (1.62 (1.12-2.33); p=0.010) and BLISS-SC (1.89 (1.39-2.57); p<0.001). A highly significant difference was observed in the pooled population (1.47 (1.25-1.72); p<0.001; adjusted for trial variance). Belimumab yielded greater BICLA response frequencies than placebo irrespective of baseline glucocorticoid dose (>7.5 or ≤7.5 mg/day of a prednisone equivalent), in patients with baseline SLEDAI-2K≥10 and in patients with positive anti-double-stranded (ds)DNA and/or low C3/C4 levels at baseline. Belimumab combined with anti-malarials yielded greater frequency of BICLA response attainment. CONCLUSIONS: In this analysis of five RCTs evaluating belimumab in SLE, belimumab conferred superiority over placebo to yield BICLA response in the overall study population and in subgroups of patients with high global or serological activity at baseline. The benefit of belimumab was more prominent when combined with anti-malarials.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Parodis I, Lindblom J, Palazzo L, et al. Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria. RMD Open. 2025. PMID: 40274305. doi:10.1136/rmdopen-2025-005444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。